A second limitation of our study is that control of diabetes could have improved in the most recent years, and different drugs have come into play since the date of data extraction (31 December 2018), however, we only included cases which had completed the loading anti-VEGF course, and with a median (IQR) of 6 (4–7) injections during the first year, the treatment patterns in the current cohort fall in line with an independent large study using real-world data.36 The gene discussed is VEGFA; the disease is diabetes mellitus.